Navigation Links
A New Era Of Hope For Neglected Diseases

After a barren period when very few therapies were introduced for neglected diseases, which kill around 3m people a year and cause the loss of the equivalent of 92m years' of healthy life, there are now over 60 drug research projects underway.

In the PLoS Medicine analysis, which is based upon a 100-page report financed by the Wellcome Trust, Mary Moran of the London School of Economics found that around three-quarters of these projects are conducted under the umbrella of drug development Public-Private Partnerships (PPPs). Thirteen of them have already reached clinical trial stage and two are awaiting regulatory approval (rectal artesunate for malaria, and paromomycin for visceral leishmaniasis). These PPP-driven projects should result in six or seven new drug registrations in the next five years.

Research by Dr Moran and her colleagues has shown that PPPs have been a critical driver of this considerable increase in activity, and that the PPP approach brings together the best skills of both public and private partners. This model consequently performs better than either sector working alone when it comes to delivering safe, effective, affordable drugs for neglected diseases.

In a linked editorial, entitled "A New Era of Hope for the World's Most Neglected Diseases", the PLoS Medicine editors argue that Moran's findings are one of several indicators that the world is finally taking action against these diseases.

For example, the Gleneagles Communiqué arising out of this year's G8 summit specifically called for increased investment to encourage the development of tools for neglected-disease control.

Citation: Moran M (2005) A breakthrough in R&D for neglected diseases: New ways to get the drugs we need. PLoS Med 2(9): e302.
http:/?​dx.doi.org/?0.1371/​journal.pmed.0020302


'"/>

Source:PLoS


Page: 1

Related biology news :

1. A New Era of Hope for the Worlds Most Neglected Diseases
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/2/2016)... 2, 2016   The Weather Company , an IBM ... an industry-first capability in which consumers will be able to ... ask questions via voice or text and receive relevant information ... Marketers have long sought an advertising solution that ... be personal, relevant and valuable; and can scale across millions ...
(Date:5/24/2016)... -- Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the ... latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Display- Ampronix News ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... ... Parallel 6 , the leading software as a service (SaaS) provider ... Patient Encounter CONSULT module which enables both audio and video telemedicine communication between the ... the CONSULT module, patients and physicians can schedule a face to face virtual patient ...
(Date:6/27/2016)... N.C. (PRWEB) , ... June 27, 2016 , ... ... commercial operations for Amgen, will join the faculty of the University of ... as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus ...
(Date:6/27/2016)...   Ginkgo Bioworks , a leading organism ... today awarded as one of the World Economic ... most innovative companies. Ginkgo Bioworks is engineering biology ... world in the nutrition, health and consumer goods ... customers including Fortune 500 companies to design microbes ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
Breaking Biology Technology: